Trial of PI-88 With Dacarbazine in Patients With Metastatic Melanoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00130442
Recruitment Status : Completed
First Posted : August 15, 2005
Last Update Posted : March 31, 2016
Progen Pharmaceuticals
Information provided by (Responsible Party):
Medigen Biotechnology Corporation

August 12, 2005
August 15, 2005
March 31, 2016
June 2005
October 2010   (Final data collection date for primary outcome measure)
The proportion of patients with objective response or stable disease (non-progression rate) after six treatment cycles [ Time Frame: after six treatment cycles ]
The proportion of patients with objective response or stable disease (non-progression rate) after six treatment cycles
Complete list of historical versions of study NCT00130442 on Archive Site
  • Non-progression rate after two and four treatment cycles [ Time Frame: after two treatment cycles and after four treatment cycles ]
  • Time to progression [ Time Frame: at the point of first radiological evidence of progressive disease ]
  • Duration of response [ Time Frame: time from commencement to radiological evidence of progression ]
  • Survival [ Time Frame: time to death and also at time-points 6 month and 12 months ]
  • Non-progression rate after two and four treatment cycles
  • Time to progression
  • Response rate
  • Duration of response
  • Survival
  • Descriptive statistics will be used in the analysis of safety and toxicity endpoints.
Not Provided
Not Provided
Trial of PI-88 With Dacarbazine in Patients With Metastatic Melanoma
A Phase II Study of PI-88 With Dacarbazine in Patients With Metastatic Melanoma

The aim of the study is to compare the safety and effectiveness of a new drug called PI-88, when used in combination with an approved chemotherapy drug called dacarbazine, in the treatment of metastatic melanoma.

PI-88 blocks new blood vessel growth in tumours (starves it of nutrients) and dacarbazine stops the cancer cells from growing. The results from this study will be analysed to see if it is worthwhile for the two drugs to be tested in future studies involving larger numbers of melanoma patients.

Metastatic melanoma is a difficult-to-treat cancer for which available treatment options are limited and minimally effective. Dacarbazine is currently one of the standard chemotherapy drugs used for the treatment of metastatic melanoma. However, it is associated with low response rates (10-20%) and median survival of less than 12 months (6-11 months in most studies). PI-88 is an antiangiogenic and antimetastatic drug that has already shown some evidence of efficacy when used alone in an intermittent dosage regimen (4 consecutive days per week) in the treatment of patients with advanced melanoma. The FDA has designated PI-88 as an Orphan Drug for this indication, as well as for Stage III and high-risk stage II disease. The aim of this randomised pilot phase II trial is to determine whether PI-88 in combination with a standard regimen of dacarbazine (1000 mg/m2 every 3 weeks) should be considered for further investigation in a larger-scale trial.
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Drug: PI-88 and dacarbazine
    190 mg daily by subcutaneous injection for PI-88 and 1000 mg/m2 on day 1 of each 21 day cycle by intravenous infusion
  • Drug: dacarbazine or DTIC
    intravenous infusion 1000 mg/m2 on day 1 of every 21 day cycle
  • Experimental: 1
    PI-88 190 mg daily by subcutaneous injection and dacarbazine 1000 mg/m2 on day 1 of each 21 day cycle
    Intervention: Drug: PI-88 and dacarbazine
  • Active Comparator: 2
    dacarbazine 1000 mg/m2 on day 1 of every 21 day cycle by intravenous infusion
    Intervention: Drug: dacarbazine or DTIC
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
October 2010
October 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Histologically proven metastatic melanoma
  • Surgery not feasible or inappropriate
  • Measurable disease. Metastatic lesions must be measurable by magnetic resonance imaging (MRI) or computed tomography (CT) as defined in Response Evaluation Criteria in Solid Tumors (RECIST), and cutaneous lesions by physical examination.
  • Have voluntarily given written informed consent to participate in this study
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 - 1
  • Life expectancy at least 3 months
  • Neutrophil count > 1.5 x 10^9/L (1,500/mm3)
  • Platelet count > 100 x 10^9/L (100,000/mm3)
  • Acceptable liver function tests (see Exclusion Criteria for maximum allowable elevations of ALT, AST, ALP and LDH)
  • PT < 1.5 x upper limit of normal (ULN)
  • APTT < 1.5 x ULN
  • Creatinine clearance > 40 mL/min, calculated using the Cockcroft-Gault formula (if just below 40 mL/min, then GFR > 40 mL/min as determined by 24-hour urine collection)

Exclusion Criteria:

  • Current or history of central nervous system involvement, brain or meningeal metastases
  • Ocular melanoma
  • Clinically significant non-malignant disease
  • Prior or co-existent malignancies (other than stage I internal malignancy where treated and disease-free for > 5 years, non-melanomatous skin cancer or in situ cancer of the cervix)
  • Prior chemotherapy
  • Prior treatment with vaccines and/or biological response modifiers within the previous 4 weeks
  • Prior treatment with radiotherapy within the previous 4 weeks (local palliative radiotherapy is permitted)
  • Radiotherapy to > 30% of marrow-bearing bone within the previous 3 months
  • Major surgery within the past 4 weeks
  • Concomitant use of aspirin (> 150 mg/day), non-steroidal anti-inflammatory drugs (except specific COX-2 inhibitors), heparin, low molecular weight heparin, warfarin (> 1 mg/day) or anti-platelet drugs (abciximab, clopidogrel, dipyridamole, ticlopidine and tirofiban). Low-dose aspirin (≤ 150 mg/day) and low-dose warfarin (≤ 1 mg/day) are permitted as concomitant medications.
  • Heparin or low molecular weight heparin within the previous 2 weeks
  • History of acute or chronic gastrointestinal bleeding within the last 2 years, inflammatory bowel disease or other abnormal bleeding tendency
  • Patients at risk of bleeding due to open wounds or planned surgery
  • Bilirubin > 1.5 x ULN
  • AST or ALT > 3 x ULN unless patient has hepatic metastases
  • LDH > 2 x ULN
  • Alkaline phosphatase > 5 x ULN, unless patient has bone metastases
  • Myocardial infarction, stroke or congestive heart failure within the past 3 months
  • Women who are pregnant or breast feeding
  • Women of childbearing potential in whom pregnancy cannot be excluded or who are not using an adequate method of contraception
  • History of allergy and/or hypersensitivity to anti-coagulants/thrombolytic agents, especially heparin
  • History of immune-mediated thrombocytopenia, thrombotic thrombocytopenic purpura or other platelet disease, or laboratory evidence of anti-heparin antibodies
  • Uncontrolled or serious infection within the past 4 weeks
  • Patients who are unable to be compliant or to follow instructions given to them by clinic staff
Sexes Eligible for Study: All
18 Years and older   (Adult, Older Adult)
Contact information is only displayed when the study is recruiting subjects
Australia,   United States
Not Provided
Not Provided
Medigen Biotechnology Corporation
Medigen Biotechnology Corporation
Progen Pharmaceuticals
Study Chair: Michael Millward, MD Sir Charles Gairdner Hospital
Principal Investigator: Anne Hamilton, PhD Sydney Cancer Centre
Principal Investigator: Damien Thomson, MD Princess Alexandra Hospital
Medigen Biotechnology Corporation
March 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP